These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7910064)

  • 1. Monitoring of cyclosporin A levels with radioimmunoassay in renal transplant recipients: comparison of monospecific and nonspecific assays.
    Lai MK; Tzen KY; Ou YC; Huang CC; Chu SH; Chuang CK; Chen HW; Chen CS
    J Formos Med Assoc; 1993 Nov; 92(11):948-52. PubMed ID: 7910064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation.
    Lindholm A; Napoli K; Rutzky L; Kahan BD
    Ther Drug Monit; 1992 Aug; 14(4):292-300. PubMed ID: 1519303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.
    Lindholm A; Dahlqvist R; Groth GG; Sjöqvist F
    Br J Clin Pharmacol; 1990 Sep; 30(3):443-52. PubMed ID: 2223423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analyses of cyclosporine in whole blood and plasma by radioimmunoassay, fluorescence polarization immunoassay, and high-performance liquid chromatography.
    Lindholm A; Henricsson S
    Ther Drug Monit; 1990 Jul; 12(4):344-52. PubMed ID: 2396308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimization of the use of cyclosporin in renal transplantation].
    Tedesco Júnior HS; Pereira AB; Luconi PS; Vaz ML; Ajzen H; Medina JO
    Rev Assoc Med Bras (1992); 1992; 38(4):183-94. PubMed ID: 1340374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic studies of cyclosporine in marrow transplant recipients. A comparison of three assay methods.
    McGuire TR; Yee GC; Emerson S; Gmur DJ; Carlin J
    Transplantation; 1992 Jun; 53(6):1272-5. PubMed ID: 1604484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
    Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
    Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the monoclonal fluorescence polarization immunoassay for cyclosporine specific? Comparison with specific radioimmunoassay.
    Armijo JA; Navarro FA; Angeles de Cos M
    Ther Drug Monit; 1992 Aug; 14(4):333-8. PubMed ID: 1519309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a monoclonal antibody fluorescent polarization immunoassay with monoclonal antibody radioimmunoassay for cyclosporin determination in whole blood.
    Alvarez JS; Sacristan JA; Alsar MJ
    Ther Drug Monit; 1992 Feb; 14(1):78-80. PubMed ID: 1546394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the immunotech cyclosporine direct radioimmunoassay for the determination of whole-blood cyclosporine in renal transplant patients.
    Westley IS; Sallustio BC; Morris RG
    Ther Drug Monit; 2005 Feb; 27(1):90-3. PubMed ID: 15665752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of cyclosporin A in whole blood and plasma in five patients with different hematocrits.
    Agarwal RP; McPherson RA; Threatte GA
    Ther Drug Monit; 1985; 7(1):61-5. PubMed ID: 3887670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the interaction between omeprazole and cyclosporine in renal transplant patients.
    Blohmé I; Idström JP; Andersson T
    Br J Clin Pharmacol; 1993 Feb; 35(2):156-60. PubMed ID: 8443034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine blood concentrations determined by different assay methods in heart transplant patients.
    Zylber-Katz E; Granit L
    Ther Drug Monit; 1989 Sep; 11(5):592-7. PubMed ID: 2815235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.
    Ducloux D; Fournier V; Rebibou JM; Bresson-Vautrin C; Gibey R; Chalopin JM
    Clin Nephrol; 1998 Apr; 49(4):232-5. PubMed ID: 9582553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation.
    Stephens E; Bolderson I; Clark B; Kinsey S; Gooi HC; Cook G
    Ann Clin Biochem; 2006 Sep; 43(Pt 5):382-8. PubMed ID: 17022881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
    Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of cyclosporin in organ transplant recipients.
    Akhlaghi F; Trull AK
    Clin Pharmacokinet; 2002; 41(9):615-37. PubMed ID: 12126456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.